Skip to main content
. 2017 Feb 3;12(2):e0171356. doi: 10.1371/journal.pone.0171356

Fig 1. Establishment of trastuzumab-resistant cell line BT-474-R and trastuzumab/lapatinib-dual resistant cell line BT-474-RL2.

Fig 1

(A) Morphological changes in parental cell line (BT-474) and its sublines (BT-474-R and BT-474-RL2). (B) MTS assay evaluating cell viability of BT-474, BT-474-R and BT-474-RL2 upon treatment with various concentrations of trastuzumab or lapatinib for 72 hours. Data are shown as means ± standard errors (SE). The assay using trastuzumab was repeated five times, and the assay using lapatinib was repeated three times.